Oncology Archives - Page 19 of 22

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer

Authors: E G Chiorean, D Von Hoff, Y Wan, S Margunato-Debay, M Botteman, D Goldstein Published: Cancer Management and Research, 2018 View publication Objectives This analysis examined changes in Karnofsky performance status...

Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases

Authors: M Botteman, V Barghout, J Stephens, J Hay, J Brandman, M Aapro Published: Annals of Oncology, 2010 View publication Background Bisphosphonates are recommended to prevent skeletal related events (SREs) in patients...

Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK

Authors: J F Logman, B M Heeg, M F Botteman, S Kaura, B A van Hout Published: Annals of Oncology, 2010 View publication Background Aromatase inhibitors are used as adjuvant therapy for...

Cost-effectiveness of zoledronic acid in the prevention of skeletal-related events in patients with bone metastases secondary to advanced renal cell carcinoma: application to France, Germany, and the United Kingdom

Authors: M F Botteman, M Meijboom, I Foley, J M Stephens, Y M Chen, S Kaura Published: European Journal of Health Economics, 2011 View publication Background The use of zoledronic acid (ZOL)...

Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours

Authors: J A Carter, A D Joshi, S Kaura, M F Botteman Published: Pharmacoeconomics, 2012 View publication Abstract Bisphosphonates reduce the risk of skeletal-related events (SREs; i.e. spinal cord compression, pathological fracture,...

Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer

Authors: J A Carter, M F Botteman Published: Expert Review Pharmacoeconomics and Outcomes Research, 2012 View publication Abstract Zoledronic acid is the only bisphosphonate approved for the prevention or delay of skeletal-related...

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents

Authors: X Gao, D Wendling, M F Botteman, J A Carter, S Rao, M Cifaldi Published: Journal of Medical Economists, 2012 View publication Objective To assess concomitant extra-articular manifestation (EAM) rates in...

Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer

Authors: S J Snedecor, J A Carter, S Kaura, M F Botteman Published: Clinical Therapy, 2012 View publication Background Denosumab has been approved in the United States for the prevention of skeletal-related...

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis

Authors: S J Snedecor, J A Carter, S Kaura, M F Botteman Published: Journal of Medical Economists, 2012 View publication Objective Denosumab has been approved in the US for skeletal-related event (SRE)...

News